AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
- Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
- Roche and Illumina partner to broaden patient access to genomic testing
- Amgen announces global diagnostic collaborations
- Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases
Research & Development
- B cells linked to effective cancer immunotherapy
- Edible 'security tag' to protect drugs from counterfeit
- Women's blood vessels age faster than men's
- Exosomes promote remarkable recovery in stroke
- Vitamin B6, leukemia's deadly addiction
- Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone
- Nuclear radiologists 'outsmart' prostate cancer with an apparently ineffective drug
Conferences & Events
- Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
- SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
- SMi's 4th Annual 3D Cell Culture
- Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
- RNA Therapeutics Conference and Focus Day
- CPhI Worldwide announces the winners of the 16th Pharma Awards
- CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023
Regulatory Affairs
- FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
- FDA approves new treatment for adults with migraine
- FDA approves first generics of Eliquis
- FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
- FDA approves new type of therapy to treat advanced urothelial cancer